PHARMA§ 01
§ 03
Practitioners, regulators, and investors who return because the conversation is worth continuing.
Contributors have held senior positions at the FDA, CMS, major PBMs, top-10 pharma companies, and leading academic medical centers. No paid placements. No sponsored content. Every guest is invited because the conversation advances the editorial mission.
§ 04
Pharma launches its full editorial platform on April 8, 2026. Early subscribers receive first-listen access twenty-four hours before public release, show notes with linked citations and primary sources, and a quarterly PDF briefing — a forty-page digest of the quarter's regulatory calendar, pipeline movements, and formulary shifts.
First-Listen Access
24 hours before public release, every episode.
Show Notes with Citations
Linked primary sources, FDA dockets, and referenced studies.
Quarterly PDF Briefing
40-page digest: regulatory calendar, pipeline readouts, formulary shifts.
No sponsored content. No paid placements. The editorial independence that makes the show worth listening to is the same independence that makes the subscriber list worth being on. Unsubscribe at any time.
